Total Pharmacy

Larry King, PharmD, discusses how pharmacy interoperability is working to create collaborative care and get pharmacists “in the game” as he says.

The order is set to make patients’ prescription costs similar to other nations with the lowest-priced drugs in the world.

Douglas Hoey, CEO of NCPA, discusses what independent pharmacies can do to handle an influx of patients and what the chain’s situation means for the pharmacy landscape.

Vin Gupta, MD, former Chief Medical Officer at Amazon Pharmacy and renowned US medical analyst, discusses pharmacists’ ability to reach communities and address social determinants of health.

Miranda Rochol, Senior Vice President of Provider Solutions at Prescryptive Health, discusses digital prescription solutions and how they are turning patients into consumers.

Brigid Groves, PharmD, MS, Vice President of Professional Affairs at APhA, discusses how the pharmacist’s role in immunization has adapted in recent history.

President of 3 Axis Advisors and CEO of 46brooklyn Research joins Drug Topics to discuss nuances surrounding pharmacy benefit managers and the way they are perceived in the public eye.

A conversation with Douglas Hoey, RPh, MBA, CEO of NCPA, on the chain pharmacy’s announcement of a second Chapter 11 bankruptcy.

In this episode of the podcast, Shawn and Jesse discuss how every situation has a solution and the best way to find it.

Douglas Hoey, CEO of NCPA, discusses what pharmacies can do to increase revenue and avoid shutting their doors.

A conversation with Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS, clinical assistant professor and director of experiential learning at West Virginia University School of Pharmacy, at AAP 2025.

Expert on drug pricing and pharmacy benefits, Antonio Ciaccia joined Drug Topics to discuss how PBMs came to hold so much control of the pharmaceutical supply chain.

A conversation with Greg Mitchell, owner of United Drug Superstore in Hatch, New Mexico, at AAP 2025.

Luke Turnock, PhD, discusses the role of pharmacists and medication counselors in addressing the challenges of increased direct-to-consumer drug advertising on social media.

Researchers explored the confidence, barriers, and role of general practice independent pharmacists regarding prescribing services within primary care settings.

Antonio Ciaccia, President of 3 Axis Advisors, CEO of 46brooklyn Research, and pharmacy benefits expert, discusses litigious, market-based, and legislative reform for pharmacy benefit managers.

Researchers identified differences in naloxone training, policies, procedures, and preferences among chain or independent pharmacies across Alabama.

A discussion with Douglas Hoey, RPh, MBA, CEO of NCPA, at AAP 2025.

CVS releases a statement shortly after HB1150 was signed in Arkansas, prohibiting pharmacy benefit managers from owning pharmacies.

LucyRx is empowering pharmacists and impacting patients’ health outcomes with its business model unlike other market-leading pharmacy benefit managers.

The 14-section order focuses on a variety of policy changes intended to make patients’ out-of-pocket costs for prescription medications more affordable in the US.

At AAP 2025, Greg Mitchell, owner of United Drug Superstore, discussed how retail pharmacies can leverage vaccine services to build long-term patient relationships.

At AAP 2025, Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS, discussed how Disney’s approach to customer service can be applied in a community pharmacy setting.

At AAP 2025, Douglas Hoey, RPh, MBA, CEO of NCPA, discussed what pharmacies can do to increase revenue and avoid shutting their doors.

At AAP 2025, Melanie Maxwell, president of AlignRx, discussed the intent, benefits and consequences of the IRA.

On behalf of 39 state and territory attorneys general, the National Association of Attorneys General issued a letter to Congress regarding major PBMs’ conflicts of interest.

Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS, discusses effective strategies for balancing excellent patient care with strict regulations surrounding controlled substances.

David Blair, CEO of LucyRx, joined Drug Topics to discuss the initiatives his company is conducting in support of a struggling pharmacy profession.